NRX Pharmaceuticals Expands Into Interventional Psychiatry with Hope Therapeutics | NewsOut

For investors in mental health and CNS treatment: NRX Pharmaceuticals is making a bold move into interventional psychiatry with Hope Therapeutics’ acquisition of a 49{d450b60efc35a2e17361b5d57bc194208ff1ac62c46bd45a026f4271e6a4dcc4} stake in Cohen & Associates, a top neuropsychiatry clinic in Florida.

In this episode of NewsOut, Ana Berry breaks down how this deal brings immediate gains in revenue and EBITDA, strengthens Hope’s National Clinic Network, and supports NRX’s broader FDA-backed pipeline for breakthrough depression and PTSD treatments like NRX 100 and NRX 101.

📊 EBITDA-positive acquisition
🏥 Strategic clinic expansion
🚀 FDA activity & fast-track pipeline
📈 Mental health investment opportunity

🏷️ Tags:
#NRXPharmaceuticals
#HopeTherapeutics
#MentalHealthInvesting
#InterventionalPsychiatry
#CNSDrugs
#Spravato
#TMS
#DepressionTreatment
#PTSDRecovery
#FDAFastTrack
#Neuropsychiatry
#HealthcareInvesting
#NewsOut
#AnaBerry